Depressing update on Orexo’s Deprexis deal

Swedish pharma Orexo (STO: ORX) and Germany-based digital therapeutics company GAIA have decided to end their partnership agreement for the former firm to commercialize the digital mental health program for depression, Deprexis, in the USA.

Both parties have reportedly analyzed the conditions for a continued partnership, and come to a decision that the rights to Deprexis will be returned to GAIA.

Nikolaj Sorensen, chief executive and president of Orexo, said: “A prerequisite for Orexo to succeed with a sophisticated digital health product like Deprexis is a tight collaboration with healthcare providers and access to viable reimbursement routes, compensating for both the product and the healthcare provider’s time.